GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Inventories, Other

Mabion (WAR:MAB) Inventories, Other : zł0.0 Mil (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Mabion Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Mabion's other inventories for the quarter that ended in Sep. 2024 was zł0.0 Mil.


Mabion Inventories, Other Historical Data

The historical data trend for Mabion's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion Inventories, Other Chart

Mabion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mabion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mabion Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Mabion Business Description

Traded in Other Exchanges
N/A
Address
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Mabion Headlines